Skip to main content
Clinical Trials/NCT07499544
NCT07499544
Not yet recruiting
Phase 3

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)

Huahui Health0 sites160 target enrollmentStarted: March 25, 2026Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Huahui Health
Enrollment
160
Primary Endpoint
Proportion of participants with HDV RNA below LLOQ with TND or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment period

Overview

Brief Summary

This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection. Eligible participants will be randomized 1:1:1 to one of three groups: libevitug 20 mg/kg group , libevitug 10 mg/kg (N=50) group, or a control/delayed treatment group (N=50). The treatment groups will receive intravenous libevitug every 2 weeks for 96 weeks, while the control group will be observed for the first 48 weeks and then receive libevitug 20 mg/kg Q2W for 48 weeks starting from Week 48.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
12 Years to 70 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Willing to sign written informed consent;
  • Male or female, aged 18-70 years; Adolescent participants with chronic HDV infection: Male or female, age ≥12 years and \<18 years at the time of signing the informed consent form (ICF)/assent;
  • Chronic HDV history with at least 6 months; For participants who are also recommended for anti-HBV therapy prior first-line NrtIs treatment (ETV, TDF, TAF) should be at least 12 weeks before the planned start of study treatment, or participant is willing to initiate first-line NrtIs treatment; HBV DNA suppressed;
  • HDV RNA ≥500 IU/mL at screening;
  • ALT \>1×ULN and \<10×ULN at screening;
  • Able to communicate well and comply with protocol.

Exclusion Criteria

  • Concomitant decompensated cirrhosis;
  • Previous or current HCC or suspicion for HCC;
  • Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis, autoimmune liver disease or other hereditary liver diseases, drug-induced liver disease or other clinically significant chronic liver diseases not caused by HDV/HBV;
  • Participants with active hepatitis C infection, or HIV infection;
  • History of other malignancies other than HCC;
  • Clinically significant ECG abnormalities at screening, which is deemed unsuitable for enrollment per investigator's discretion;
  • Alcohol abuse or drug addiction within 1 year;
  • Participants who have participated in clinical trials of any drug or medical device within 1 month before randomization;
  • Pregnant, lactating women, or women of childbearing potential with a positive pregnancy test;
  • Any other clinically significant abnormal lab result, severe acute/chronic medical/psychiatric condition, concomitant serious systemic disease.

Arms & Interventions

Libevitug 20 mg/kg

Experimental

Participants will receive libevitug at a dose of 20 mg/kg Q2W via intravenous infusion for 96 weeks

Intervention: Libevitug 20 mg/kg (Drug)

Libevitug 10 mg/kg

Experimental

Participants will receive libevitug at a dose of 10 mg/kg Q2W via intravenous infusion for 96 weeks

Intervention: Libevitug 10 mg/kg (Drug)

Control group/delayed treatment with libevitug 20 mg/kg

Active Comparator

Participants will be observed as comparator for 48 weeks, then to receive libevitug 20 mg/kg for 48 weeks

Intervention: Delayed treatment with libevitug (Other)

Outcomes

Primary Outcomes

Proportion of participants with HDV RNA below LLOQ with TND or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment period

Time Frame: Week 48

Proportion of participants with HDV RNA below Lower Limit of Quantification (LLOQ) with target not detected (TND) or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment period

Secondary Outcomes

  • Change from baseline in Model for End-Stage Liver Disease (MELD) score at different time points(up to week 96)
  • Change from baseline in Child-Pugh score at different time points during the treatment period, extended treatment period and follow-up period. (A higher Child-Pugh score indicates poorer liver function, more severe disease, and a worse prognosis)(up to week 96)
  • Percentage of participants with treatment-emergent adverse events (TEAEs)(up to week 120)
  • Ctrough,ss(up to week 96)
  • Liver related clinical events(up to week 120)
  • Change from baseline in MELD score at different time points(up to week 96)
  • Change from baseline in Child-Pugh score at different time points(up to week 96)
  • Proportion of participants with HDV RNA below LLOQ or a decrease of ≥ 2 log10 from baseline, and ALT normalization(up to week 96)
  • Proportion of participants with HDV RNA below LLOQ or a decrease of ≥ 2 log10 from baseline(up to week 96)
  • Proportion of participants with plasma HDV RNA achieving HDV RNA < LLOQ(up to week 96)
  • Proportion of participants with ALT normalization(up to week 96)
  • Change from baseline in liver stiffness measurement (LSM)(up to week 96)
  • Change from baseline in plasma HDV RNA levels at different time points(up to week 96)
  • AEs, abnormal findings in physical examination, vital signs and lab tests(up to week 120)
  • PK analysis(up to week 120)

Investigators

Sponsor
Huahui Health
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials